External Validation of the Lupus Impact Tracker in a Southeastern US Longitudinal Cohort With Systemic Lupus Erythematosus. Issue 6 (9th May 2017)

• Record Type: Journal Article
• Authors: Brandt, Jennifer E.; Drenkard, Cristina; Kan, Hong; Bao, Gaobin; Dunlop‐Thomas, Charmayne; Pobiner, Bonnie; Chang, David J.; Jolly, Meenakshi; Lim, S. Sam
• Is Part Of: Arthritis care & research. Volume 69:Issue 6(2017:Jun.)
• Page Start: 842
• Page End: 848
• Publication Date: 2017-05-09
• Subjects: Arthritis -- Periodicals; Rheumatism -- Periodicals; 616.72
• DOI: 10.1002/acr.23009
• Languages: English
• ISSNs: 2151-464X

Abstract

Abstract : Objective: To examine the external validity of the Lupus Impact Tracker (LIT), a systemic lupus erythematosus (SLE)‐specific, health‐related quality of life (HRQoL) tool in a population‐based cohort of patients with SLE in Atlanta, Georgia. We modeled the association of LIT scores with patient‐reported measures of SLE activity (Systemic Lupus Activity Questionnaire [SLAQ]) and organ damage (self‐administered Brief Index of Lupus Damage [SA‐BILD]). We investigated the association of LIT scores with general HRQoL using the Short Form 12 (SF‐12). Methods: Correlation, multivariable regression, and longitudinal analyses using general linear modeling with fixed effects were performed to investigate the association between the LIT and patient‐reported disease activity (SLAQ); patient‐reported disease damage (SA‐BILD); mental health (mental component summary [MCS] of the SF‐12); and physical health (physical component summary [PCS] of the SF‐12). Demographic trends related to the LIT were also assessed using cross‐sectional analysis. Results: The LIT was significantly associated with disease activity (SLAQ), organ damage (SA‐BILD), MCS scores, and PCS scores in both adjusted and unadjusted regression analysis ( P < 0.0001). Longitudinal analysis demonstrated a significant association between the LIT and disease activity (SLAQ), MCS scores, and PCS scores ( P < 0.0001), but not organ damage (SA‐BILD). Conclusion: The LIT is a simple, patient‐centered tool that can be used to assess HRQoL in patients with SLE. This study provides external validity of the LIT in a population‐based cohort with a large number of African American patients with a relatively high disease burden.